Abivax (ABVX) Profit After Tax (2022 - 2026)
Abivax (ABVX) posted quarterly Profit After Tax of $56.7 million for Q1 2026, up 3.01% year-over-year from $55.1 million in Q1 2025, and up 108.26% quarter-over-quarter from -$687.1 million in Q4 2025.
Abivax (ABVX) Profit After Tax (2022 - 2026) Analysis & Trends
Abivax's Profit After Tax history runs 5 years deep, the most recent figure standing at $56.7 million for Q1 2026.
- In Q1 2026, Profit After Tax rose 3.01% year-over-year to $56.7 million; the TTM figure through Mar 2026 stood at -$396.2 million (down 123.8% YoY), while the FY2025 annual figure was -$391.2 million, down 107.79% from the prior year.
- Profit After Tax for Q1 2026 stood at $56.7 million, up from -$687.1 million in the prior quarter.
- The five-year high for Profit After Tax was $179.3 million in Q3 2025, with the low at -$687.1 million in Q4 2025.
- The 5-year median for Profit After Tax is $46.6 million (2024), against an average of -$47.9 million.
- The sharpest annual moves came in 2024 and 2025: Profit After Tax plunged 210940865.76% in 2024, then surged 195.6% in 2025.
- Abivax's Profit After Tax stood at -$61.93 in 2022, then slumped by 156.09% to -$158.59 in 2023, then slumped by 210940865.76% to -$334.5 million in 2024, then slumped by 105.38% to -$687.1 million in 2025, then surged by 108.26% to $56.7 million in 2026.
- Business Quant data shows ABVX's Profit After Tax at $56.7 million in Q1 2026, -$687.1 million in Q4 2025, and $179.3 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | PAT (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 1.10 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 1.30 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 472.00 Mn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | -644.37 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 237.01 Mn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | -3,087.27 |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 81.49 Mn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 164.49 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | -16.62 Mn |
| 10 | Abivax | 9.39 Bn | 9.39 Bn | - | 56.74 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 56.74 Mn |
| Dec 31, 2025 | -687.07 Mn |
| Sep 30, 2025 | 179.28 Mn |
| Jun 30, 2025 | 54.80 Mn |
| Mar 31, 2025 | 55.09 Mn |
| Dec 31, 2024 | -334.54 Mn |
| Sep 30, 2024 | 60.65 Mn |
| Jun 30, 2024 | 41.75 Mn |
| Mar 31, 2024 | 46.57 Mn |
| Dec 31, 2023 | -158.59 |
| Dec 31, 2022 | -61.93 |